ASH 2022 | Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of acalabrutinib plus venetoclax and rituximab (AVR) in patients with mantle cell lymphoma (MCL). Prof. Wang then goes on to discuss the importance of chemotherapy-free regimens and where these may fit in the MCL treatment landscape, and concludes by commenting on the growing role of targeted immunotherapy combinations. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Deciphera: Consultancy; BioInvent: Consultancy, Honoraria, Research Funding; Juno Therapeutics: Consultancy, Research Funding; IDEOlogy Health: Honoraria; Celgene: Research Funding; VelosBio: Consultancy, Research Funding; Molecular Templates: Research Funding; Loxo Oncology: Research Funding; Dava Oncology: Honoraria; Oncternal: Consultancy, Research Funding; Genmab: Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Leukemia & Lymphoma Society: Consultancy, Honoraria; MJH Life Sciences: Honoraria; Medscape: Honoraria; Pepromene Bio: Consultancy; Eastern Virginia Medical School: Honoraria; LLC TS Oncology: Honoraria; Studio ER Congressi: Honoraria; Oncology Specialty Group: Honoraria; Moffit Cancer Center: Honoraria; OncLive: Honoraria; Physicians Education Resources (PER): Honoraria; Practice Point Communications (PPC): Honoraria; Meeting Minds Experts: Honoraria; Genentech: Consultancy, Research Funding; Milken Institute: Consultancy; Merck: Honoraria; Lilly: Consultancy, Research Funding; Kite Pharma: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; InnoCare: Consultancy, Research Funding; Vinverx: Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Acerta Pharma: Honoraria, Research Funding; AbbVie: Consultancy.
